Eliminating the high-risk CTV1 margin in DAHANCA oropharyngeal radiotherapy: Dosimetric impact on dysphagia and organ-at-risk doses. - Hansen CR; Bertelsen AS; Hazell I; Stougaard SW; Johansen J; Overgaard J; Eriksen JG; Zukauskaite R (Acta oncologica (Stockholm, Sweden), 2025)